Shanghai Cell Therapy Group Overview
- Year Founded
-
2013
- Status
-
IPO Registration
- Employees
-
1,144
- Latest Deal Type
-
IPO
- (Announced)
- Investors
-
14
Shanghai Cell Therapy Group General Information
Description
Developer of tumour immune cell therapy treatments. The company operates a cellular diagnosis center and provides immune cell research and treatment services. The company is involved in cellular cold storage, cellular pharmaceuticals, antibody research, enabling patients to do genetic testing and providing research data to cancer facilities.
Contact Information
Website
www.shcell.comCorporate Office
- Building 6, No. 1585 Yuanguo Road
- Anting Town, Jiading District
- Shanghai, 201805
- China
Corporate Office
- Building 6, No. 1585 Yuanguo Road
- Anting Town, Jiading District
- Shanghai, 201805
- China
Shanghai Cell Therapy Group Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. IPO | 30-Apr-2024 | Announced | Generating Revenue | |||
| 11. Secondary Transaction - Private | 13-Dec-2023 | Completed | Generating Revenue | |||
| 10. Later Stage VC (Series D2) | 08-Feb-2022 | Completed | Generating Revenue | |||
| 9. Later Stage VC (Series D1) | 23-Mar-2021 | Completed | Generating Revenue | |||
| 8. Secondary Transaction - Private | 26-Feb-2021 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series C2) | 01-Dec-2018 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series C1) | 01-Oct-2018 | Completed | Generating Revenue | |||
| 5. Secondary Transaction - Private | 26-Jun-2018 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series B2) | 08-Nov-2017 | $9.1M | $58.4M | Completed | Generating Revenue | |
| 3. Early Stage VC (Series B1) | 18-Apr-2016 | $28.5M | $49.4M | Completed | Generating Revenue |
Shanghai Cell Therapy Group Comparisons
Industry
Financing
Details
Shanghai Cell Therapy Group Competitors (35)
One of Shanghai Cell Therapy Group’s 35 competitors is CureGenetics, a Venture Capital-Backed company based in Suzhou, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CureGenetics | Venture Capital-Backed | Suzhou, China | ||||
| NeoX Biotech | Venture Capital-Backed | Beijing, China | ||||
| Mabworks Biotech | Venture Capital-Backed | Beijing, China | ||||
| Marengo Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
| Xenetic Biosciences | Corporation | Framingham, MA |
Shanghai Cell Therapy Group Patents
Shanghai Cell Therapy Group Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026145457-A1 | Truncated transposase, transposon system, and use thereof | Pending | 30-Dec-2024 | ||
| WO-2026139059-A1 | Polynucleotide for enhancing polypeptide expression, and nucleic acid construct and use thereof | Pending | 26-Dec-2024 | ||
| WO-2026139087-A1 | Polynucleotide for enhancing polypeptide expression, and nucleic acid construct and use thereof | Pending | 26-Dec-2024 | ||
| WO-2026109027-A1 | Multispecific antigen-binding molecule and use thereof | Pending | 22-Nov-2024 | ||
| WO-2026082016-A1 | Chimeric promoter having high activity in activated immune cells | Pending | 14-Oct-2024 | C12N15/113 |
Shanghai Cell Therapy Group Signals
Shanghai Cell Therapy Group Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Xiyang Investment | Venture Capital | Minority | ||
| CCB International | PE/Buyout | Minority | ||
| Jiangsu Jiuzhou Venture Capital Management | Growth/Expansion | Minority | ||
| Shanghai Shengshi Capital Management | Growth/Expansion | Minority | ||
| China Pacific Life Insurance | Asset Manager | Minority |
Shanghai Cell Therapy Group FAQs
-
When was Shanghai Cell Therapy Group founded?
Shanghai Cell Therapy Group was founded in 2013.
-
Where is Shanghai Cell Therapy Group headquartered?
Shanghai Cell Therapy Group is headquartered in Shanghai, China.
-
What is the size of Shanghai Cell Therapy Group?
Shanghai Cell Therapy Group has 1,144 total employees.
-
What industry is Shanghai Cell Therapy Group in?
Shanghai Cell Therapy Group’s primary industry is Biotechnology.
-
Is Shanghai Cell Therapy Group a private or public company?
Shanghai Cell Therapy Group is a Private company.
-
What is Shanghai Cell Therapy Group’s current revenue?
The current revenue for Shanghai Cell Therapy Group is .
-
How much funding has Shanghai Cell Therapy Group raised over time?
Shanghai Cell Therapy Group has raised $285M.
-
Who are Shanghai Cell Therapy Group’s investors?
Xiyang Investment, CCB International, Jiangsu Jiuzhou Venture Capital Management, Shanghai Shengshi Capital Management, and China Pacific Life Insurance are 5 of 14 investors who have invested in Shanghai Cell Therapy Group.
-
Who are Shanghai Cell Therapy Group’s competitors?
CureGenetics, NeoX Biotech, Mabworks Biotech, Marengo Therapeutics, and Xenetic Biosciences are some of the 35 competitors of Shanghai Cell Therapy Group.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process